Anvisa Authorises the Import of Experimental Medicinal Product for Lito Sousa
13 Articles
13 Articles
Lito was included in the company's compassionate use program and will receive the substance in Brazil.
Influencer with Creutzfeldt-Jakob disease will be the first to receive the substance
Substance ALN-6457, of Regeneron Pharmaceuticals, has not yet been registered in Brazil and will be used exceptionally in the treatment of Lito Sousa after Einstein's request
This content was originally published in Agora RN - Rio Grande do Norte News Portal. Visit https://agorarn.com.br for more Christmas and RN news. The National Agency for Health Surveillance (Anvisa) authorized, on Friday 4, the importation and exceptional use of the experimental drug ALN-6457 for the treatment of the influencer Lito Sousa, 59 years old, diagnosed with Creutzfeldt-Jakob disease (DCJ). The drug is still in stage prior to clinical …
The influencer Lito Sousa will be the first patient in the world to use the experimental drug ALN-6457 in the treatment of Creutzfeldt-Jakob disease. The National Agency for Health Surveillance (Anvisa) authorized the import of the substance on Friday (4), in response to an exceptional request. The release took place through a special process, because the [...]
Exceptional authorization allows importation of therapy still under development for the influencer, diagnosed with Creutzfeldt-Jakob disease
Coverage Details
Bias Distribution
- 50% of the sources lean Left, 50% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
